https://www.selleckchem.com/pr....oducts/H-89-dihydroc
Recent studies suggest that statins are underprescribed in patients living with HIV (PLWH) at risk for atherosclerotic cardiovascular disease (ASCVD), but none have assessed if eligible patients receive the correct statin and intensity compared to uninfected controls. The primary objective was to determine whether statin-eligible PLWH are less likely to receive appropriate statin therapy compared to patients without HIV. This retrospective study evaluated statin eligibility and prescribing among patients in both an HIV and
Me gusta
Comentario
Compartir
